New efficacy data for Pfizer's 4-1BB, OX40 programs

Abstracts published ahead of next month's American Society of Clinical Oncology (ASCO) meeting included data for a pair of next-generation immuno-oncology programs from Pfizer Inc. (NYSE:PFE). The antibodies, PF-5082566 ( PF-2566) and PF-04518600, are in Phase I testing.

PF-5082566 is an agonist of tumor necrosis factor (TNF) receptor superfamily member 9 ( TNFRSF9; 4-1BB; CD137). It was developed using HuCAL technology from MorphoSys AG (Xetra:MOR; Pink:MPSYF). PF-04518600 antagonizes TNF receptor superfamily member 4 ( OX40). ...